Aortic Aneurysms — Med2Date

📋 Key Information Summary

📋

AAA screening: Ultrasound screening is recommended for all men aged ≥65 years. One-off screening reduces AAA-related mortality by approximately 42%. No routine screening recommended for women in the general population.
Size thresholds for intervention: Abdominal aortic aneurysm — elective repair recommended when diameter ≥5.5 cm (men) or ≥5.0 cm (women), or rapid growth >1 cm/year. Thoracic aortic aneurysm — surgical threshold generally ≥5.5 cm for degenerative, ≥5.0 cm for Marfan/Loeys-Dietz, and ≥4.5 cm with bicuspid aortic valve plus additional risk factors.
Rupture risk rises exponentially with diameter: <1% per year at <5 cm, ~5% at 5–5.9 cm, ~10% at 6–6.9 cm, and ~20% at ≥7 cm. Rupture carries an overall mortality exceeding 80%.
EVAR vs open repair: Endovascular aneurysm repair (EVAR) offers lower 30-day mortality but requires lifelong surveillance imaging and higher reintervention rates. Open repair has superior long-term durability. Shared decision-making is essential.
Genetic aortopathies (Marfan syndrome, Loeys-Dietz syndrome, vascular Ehlers-Danlos syndrome) require early specialist referral, family cascade screening, serial imaging, and tailored pharmacotherapy.
Blood pressure control is the cornerstone of medical management. Target <130/80 mmHg. Beta-blockers are first-line in Marfan syndrome to slow aortic root dilation.
Smoking cessation is the single most modifiable risk factor for AAA growth and rupture. Offer nicotine replacement therapy, varenicline, or bupropion alongside behavioural support.
Statin therapy (atorvastatin or rosuvastatin) is recommended for all patients with aortic aneurysm irrespective of lipid levels to reduce cardiovascular events.
Surveillance intervals: AAA 3.0–3.9 cm — repeat ultrasound every 2 years; 4.0–4.9 cm — every 12 months; 5.0–5.4 cm — every 3–6 months. TAA — CT or MRI at 6- to 12-monthly intervals depending on size and etiology.
Abdominal pain, hypotension, or syncope in a patient with a known aneurysm is a vascular emergency — arrange immediate CT angiography and urgent vascular surgery consultation.
ATSI populations have lower documented AAA prevalence but higher rupture mortality due to delayed presentation and limited access to vascular surgical services in remote and rural communities.
First-degree relatives of patients with AAA should be offered screening ultrasound (≥2% prevalence when index case is male). Genetic referral is indicated for all patients presenting <60 years or with family history of aortic dissection.

Introduction & Australian Epidemiology

Aortic aneurysm is a localised, permanent dilation of the aorta exceeding 50% of the normal expected diameter. Aneurysms may involve the thoracic aorta (ascending, arch, or descending), the abdominal aorta (infrarenal most commonly), or both (thoraco-abdominal). The condition is often asymptomatic until catastrophic rupture or dissection occurs, earning its reputation as a "silent killer."

In Australia, aortic aneurysm and dissection accounted for approximately 2,100 deaths in 2022, representing a significant cardiovascular mortality burden (Australian Bureau of Statistics). The age-standardised mortality rate has declined over the past two decades, largely attributable to increased detection through screening programmes and improvements in elective surgical outcomes.

📊

Australian prevalence data: The Australian AAA screening programme (modelled on the UK National AAA Screening Programme) has identified a prevalence of approximately 4.5–7.7% in men aged 65–74 years. Prevalence is higher in current and ex-smokers, those with hypertension, and individuals with a family history of AAA. Indigenous Australians appear to have lower prevalence but disproportionately higher rupture-related mortality.

Key epidemiological points for the Australian context include:

AAA is 4–6 times more common in men than women
Peak incidence occurs in the 65–85 age group
Smoking increases AAA risk 3–7 fold and is the strongest modifiable risk factor
First-degree relatives of affected individuals have a 2–4 fold increased risk
Thoracic aortic aneurysms are less common (approximately 6 per 100,000 person-years) but carry significant morbidity from dissection and rupture
The National Vascular Disease Prevention Alliance recommends integration of AAA screening with existing cardiovascular risk assessments in primary care

Screening & Surveillance

Abdominal Aortic Aneurysm Screening

Screening for AAA with abdominal ultrasound is a cost-effective public health strategy. The primary aim is to identify aneurysms before rupture, allowing timely elective repair with significantly lower perioperative mortality (4–5% elective repair vs >40–50% emergency rupture repair).

✅

Recommendation (NHMRC/PSA): One-off abdominal ultrasound screening is recommended for all men aged ≥65 years. Current smokers and ex-smokers should be prioritised. There is insufficient evidence to support population-level screening in women; however, screening is reasonable in women with cardiovascular risk factors equivalent to those in men.

Who to Screen

Population	Recommendation	Evidence Level
All men aged ≥65 years	One-off ultrasound screening (strong recommendation)	Level I (multiple RCTs)
Men aged 50–65 with ≥1 risk factor (smoking, hypertension, family history, hyperlipidaemia)	Consider screening ultrasound (conditional recommendation)	Level II
First-degree relatives of AAA patients (any sex)	Ultrasound screening from age 50, or 10 years younger than index case age at diagnosis	Level III
Women aged ≥65 with cardiovascular risk factors	Consider screening (individualised)	Level III
Patients with known peripheral or coronary artery disease	Ultrasound if not previously imaged	Level III

Surveillance Protocols by Aneurysm Size

Once an aneurysm is identified, the frequency of surveillance imaging depends on the aneurysm diameter, growth rate, morphology, and patient fitness for eventual intervention.

Low Risk

AAA 3.0–3.9 cm

Repeat ultrasound every 2 years. Reinforce smoking cessation and cardiovascular risk factor management.

Setting: GP surveillance with vascular referral available

Moderate Risk

AAA 4.0–4.9 cm

Repeat ultrasound every 12 months. Vascular surgery referral for assessment. Optimise medical therapy.

Setting: Vascular surgery outpatient review

High Risk

AAA 5.0–5.4 cm

Surveillance every 3–6 months with CT angiography for operative planning. Discuss elective repair if fit for surgery.

Setting: Vascular surgery with MDT discussion

🚨

Intervention threshold: Elective repair (EVAR or open) is recommended when AAA reaches ≥5.5 cm (men) or ≥5.0 cm (women), when growth rate exceeds >1 cm/year, or when symptomatic (pain, tenderness). Saccular morphology warrants earlier surgical consideration regardless of size.

Thoracic Aortic Aneurysm Surveillance

TAA surveillance is guided by etiology, baseline size, growth rate, and presence of genetic syndromes. Imaging modalities include transthoracic echocardiography (for the ascending aorta), CT angiography, and MRI (preferred in younger patients to reduce cumulative radiation exposure).

Aortic Size	Imaging Interval	Modality
<4.0 cm (degenerative)	Every 12 months, then every 2–3 years if stable	Echocardiography ± MRI
4.0–4.9 cm	Every 6–12 months	CT or MRI
≥5.0 cm	Every 3–6 months	CT angiography (pre-operative planning)
Genetic aortopathy (any size)	Every 6–12 months (lifelong)	MRI preferred
Bicuspid aortic valve	Baseline imaging; repeat every 3–5 years if <4.0 cm, annually if ≥4.0 cm	Echocardiography ± MRI

Genetic Syndrome Screening

Patients with Marfan syndrome, Loeys-Dietz syndrome, vascular Ehlers-Danlos syndrome, Turner syndrome, or bicuspid aortic valve with aortopathy require lifelong aortic surveillance. Family cascade screening using genetic testing and/or imaging is mandatory. Referral to a clinical genetics service is recommended (available at major tertiary centres: Royal Melbourne Hospital, Royal Prince Alfred Sydney, Royal Brisbane and Women's Hospital).

Thoracic Aortic Aneurysm (TAA)

Thoracic aortic aneurysms involve dilation of the ascending aorta (>70% of cases), aortic arch, or descending thoracic aorta. TAA is less common than AAA but carries a high risk of acute aortic dissection and rupture. The natural history is influenced by etiology, growth rate, and associated connective tissue disorders.

Etiology

Etiology	Proportion	Key Features
Degenerative / Atherosclerotic	~60%	Most common in older adults (>65 years), associated with hypertension, smoking, hyperlipidaemia. Typically involves the ascending aorta or descending aorta.
Genetic / Connective Tissue	~20%	Marfan syndrome (fibrillin-1 mutation), Loeys-Dietz syndrome (TGFBR1/2), vascular Ehlers-Dietz (COL3A1). Earlier onset, more aggressive growth.
Bicuspid Aortic Valve (BAV)	~10–15%	Present in 1–2% of the population. Aortopathy independent of valve haemodynamics — mediated by extracellular matrix defects. Ascending aorta predominantly affected.
Inflammatory / Infectious	~5%	Giant cell arteritis, Takayasu arteritis, tertiary syphilis (now rare), mycotic aneurysm.
Post-dissection	Variable	Chronic residual dissection flap with false lumen aneurysmal dilation. Requires close surveillance.

Size Thresholds for Surgery

Surgical thresholds are guided by aneurysm diameter, etiology, rate of growth, presence of symptoms, and concomitant cardiac surgery requirements. The following thresholds apply to elective intervention:

⚠️

Ascending aorta surgical thresholds:

Degenerative TAA: ≥5.5 cm
Marfan syndrome: ≥5.0 cm (or ≥4.5 cm with additional risk factors — family history of dissection, rapid growth >0.5 cm/year, severe aortic regurgitation, desire for pregnancy)
Loeys-Dietz syndrome: ≥4.5 cm (earlier intervention due to higher dissection risk at smaller diameters)
Bicuspid aortic valve: ≥5.5 cm alone; ≥4.5 cm if undergoing concomitant aortic valve replacement; ≥5.0 cm with additional risk factors (coarctation, family history, hypertension)
Descending TAA: ≥6.0–6.5 cm (open or TEVAR)

Growth Rates

Understanding growth rates is essential for surgical timing and surveillance intervals:

Degenerative TAA: mean growth ~0.1–0.2 cm/year; faster in the descending aorta
Marfan syndrome: mean growth ~0.2–0.3 cm/year; may accelerate during pregnancy
Loeys-Dietz syndrome: growth rates variable, often faster than Marfan; 0.4–0.5 cm/year reported
Bicuspid aortic valve: growth ~0.1–0.2 cm/year, similar to degenerative
Post-dissection: growth may be rapid in the first year; stabilises in chronic phase
Growth >0.5 cm in 6 months or >1 cm in 12 months is an indication for intervention regardless of absolute diameter

Abdominal Aortic Aneurysm (AAA)

Abdominal aortic aneurysm is the most common form of aortic aneurysm, predominantly involving the infrarenal aorta (90–95% of cases). AAA is a disease of ageing with a strong association with atherosclerosis, smoking, and hypertension. Rupture of AAA remains a leading cause of preventable death in older Australians.

Risk Factors

Risk Factor	Relative Risk / Odds Ratio	Comment
Male sex	OR 4–6	AAA is predominantly a disease of men; women have later onset but worse outcomes
Age >65 years	Incidence rises steeply	Mean age at diagnosis: 70–75 years
Current smoking	OR 3–7	Dose-response relationship. Accelerates growth and increases rupture risk 4-fold.
Family history (1st degree)	OR 2–4	Screen siblings and offspring. Genetic predisposition (9p21 locus, DAB2IP variants).
Hypertension	OR 1.5–2.5	Contributes to wall stress and aneurysm progression
Hyperlipidaemia	OR 1.2–1.5	Weaker association than for coronary disease; statins still recommended
COPD / Emphysema	OR 1.5–2.0	Shared smoking aetiology; elastin degradation in lung and aortic wall
Peripheral artery disease	OR 2–3	Warrants ultrasound screening for AAA

Rupture Risk by Diameter

The risk of AAA rupture increases exponentially with diameter and is also influenced by gender (women have higher rupture risk at any given size), blood pressure control, and smoking status.

Low Risk

<5.0 cm

Annual rupture risk <1%. Surveillance with conservative management. No elective repair indicated.

Setting: GP-led surveillance

Moderate Risk

5.0–5.9 cm

Annual rupture risk ~3–5%. Consider elective repair in surgical candidates. MDT decision-making recommended.

Setting: Vascular surgery MDT

High Risk

≥6.0 cm

Annual rupture risk ~10–20%. Elective repair strongly recommended if physiologically fit. Intervention threshold met.

Setting: Tertiary vascular surgery centre

🚨

Ruptured AAA: Presents with the classic triad of abdominal/back pain, hypotension, and a pulsatile abdominal mass (present in only ~50% of cases). Overall mortality exceeds 80% (including pre-hospital deaths). Immediate resuscitation, permissive hypotension (target systolic 80–90 mmHg), massive transfusion protocol activation, and emergent CT angiography (if haemodynamically permitting) with immediate transfer to the operating theatre are required. MBS item 35200 covers emergency AAA repair.

EVAR vs Open Repair

The choice between endovascular aneurysm repair (EVAR) and open surgical repair depends on aneurysm anatomy, patient comorbidities, fitness for surgery, and patient preference. Both techniques are available at major Australian vascular centres.

Feature	EVAR	Open Repair
Approach	Percutaneous femoral artery access; stent-graft deployment	Midline laparotomy or retroperitoneal approach; prosthetic graft interposition
30-day mortality	1–2%	4–5%
Long-term survival	Similar to open at 5 years	Superior beyond 5–8 years in fit patients
Reintervention rate	Higher (20–30% at 5 years — endoleak, graft migration)	Lower (<5% at 5 years)
Surveillance requirement	Lifelong CT/ultrasound (30 days, 6 months, 12 months, then annually)	Less intensive — clinical follow-up with imaging if symptoms
Suitable anatomy	Adequate neck length (≥15 mm), iliac access, no severe angulation	Hostile anatomy, short neck, young patients, connective tissue disease
Hospital stay	2–3 days	7–10 days
Recovery	2–4 weeks	6–12 weeks

⚠️

EVAR is NOT recommended in patients with connective tissue disorders (Marfan, Loeys-Dietz, vascular EDS) due to progressive aortic degeneration and high risk of device failure. Open repair is the preferred approach in these patients.

Post-EVAR Surveillance Protocol (Australian Practice)

30 days: CT angiography (baseline post-implant)
6 months: Duplex ultrasound ± CT if endoleak suspected
12 months: CT angiography
Annually thereafter: Duplex ultrasound (CT reserved for abnormal findings or suspected endoleak)
Lifelong surveillance — no "discharge" from follow-up

Genetic Aortopathies

Genetic aortopathies are a group of heritable connective tissue disorders characterised by progressive aortic dilation, dissection, and rupture at younger ages and smaller aortic diameters than degenerative aneurysms. Early recognition, genetic testing, and family cascade screening are essential to reduce morbidity and mortality.

Marfan Syndrome

Marfan syndrome is an autosomal dominant disorder caused by mutations in the FBN1 gene encoding fibrillin-1, affecting approximately 1 in 5,000 individuals. Diagnosis is based on the revised Ghent criteria (2010), incorporating aortic root Z-score, ectopia lentis, systemic score, and genetic testing.

💊

Atenolol

Noten® · Generic · β1-selective blocker

Adult dose 25–50 mg PO BD, titrate to 50–100 mg BD (target HR <60 bpm at rest)

Paediatric dose 1–2 mg/kg/day PO divided BD (max 2 mg/kg/day)

Route Oral

Renal adjustment eGFR <30 mL/min: reduce dose by 50%

PBS status ✔ PBS General Benefit

💊

Losartan

Cozaar® · Generic · ARB (angiotensin II receptor blocker)

Adult dose 25 mg PO daily, titrate to 50–100 mg daily

Paediatric dose 0.7 mg/kg/day PO daily (max 50 mg/day)

Route Oral

Renal adjustment No specific adjustment; monitor potassium and creatinine

PBS status ✔ PBS General Benefit

Management principles for Marfan syndrome:

Beta-blockers (atenolol or metoprolol) are first-line to reduce aortic root dilation rate
Losartan (ARB) may be added or used as an alternative — based on evidence showing reduced TGF-β signalling; trials (COMPARE, Aortic Marfan) show benefit when combined with beta-blockers
Surgical threshold: aortic root ≥5.0 cm, or ≥4.5 cm with additional risk factors (family history of dissection, rapid growth, desire for pregnancy, severe AR)
Prophylactic aortic root replacement (David procedure — valve-sparing) is preferred over Bentall (composite valve-graft) in suitable patients
Avoid competitive sport, isometric exercise, and contact activities
Pregnancy requires pre-conception counselling; consider prophylactic root replacement if aortic root ≥4.5 cm before conception

Loeys-Dietz Syndrome

Loeys-Dietz syndrome (LDS) is caused by mutations in TGFBR1, TGFBR2, SMAD3, TGFB2, or TGFB3. Characterised by aortic and arterial aneurysms and tortuosity, hypertelorism, bifid uvula or cleft palate, and arterial tortuosity. Dissection can occur at diameters smaller than seen in Marfan syndrome.

🚨

Critical difference from Marfan: LDS patients may dissect at aortic diameters <4.0 cm. Surgical intervention is recommended at ≥4.5 cm for the ascending aorta (or ≥4.0 cm at experienced centres). Imaging should include the entire arterial tree — cerebral, thoracic, abdominal, and iliac vessels — due to risk of aneurysms at any location.

Vascular Ehlers-Danlos Syndrome (Type IV)

Vascular EDS is caused by mutations in COL3A1 and is characterised by arterial dissection and rupture, organ rupture (bowel, uterus), thin translucent skin, and characteristic facial features. Life expectancy is markedly reduced (median ~50 years).

Surgery is high risk — tissue fragility leads to poor wound healing, anastomotic dehiscence, and vascular complications
Celiprolol (a β1-blocker with β2-agonist properties) has shown benefit in reducing arterial events (European trial data) — not currently PBS-listed in Australia; may be available via Special Access Scheme
Avoid invasive angiography and unnecessary surgery
Medical management with blood pressure optimisation is the mainstay
Genetic counselling and prenatal/preimplantation genetic testing should be discussed

Family Screening Protocol

Condition	Screening Method	Age to Start	Frequency
Marfan syndrome	Genetic testing + echocardiography	At diagnosis or birth (if family history known)	Echo every 12 months (6-monthly if aortic dilation)
Loeys-Dietz syndrome	Genetic testing + CT/MRI arterial imaging	At diagnosis or infancy	Imaging every 6–12 months
Vascular EDS	Genetic testing + MRA (avoid arterial catheterisation)	At diagnosis	Imaging annually or as clinically indicated
Bicuspid aortic valve aortopathy	Echo + MRI if ascending dilation	At time of BAV diagnosis	Every 3–5 years if <4.0 cm; annually if ≥4.0 cm
Familial AAA (1st degree relative)	Abdominal ultrasound	Age 50 or 10 years before index diagnosis	Every 5 years if normal; per size-based protocol if abnormal

Australian genetic testing: Genetic testing for heritable aortopathies is available through clinical genetics services at major tertiary hospitals and commercial laboratories (e.g., Sonic Genetics, Douglass Hanly Moir). Medicare rebate is available under MBS items 73286–73304 for targeted gene panels when clinical criteria are met.

Medical Management

Medical management of aortic aneurysms aims to slow aneurysm growth, reduce cardiovascular events, and minimise the risk of rupture. The three pillars of medical therapy are blood pressure control, smoking cessation, and statin therapy, with disease-specific modifications for genetic aortopathies.

Blood Pressure Control

Hypertension is a major modifiable risk factor for both aneurysm growth and rupture. Target blood pressure is <130/80 mmHg in all patients with aortic aneurysm (per ESC 2024 and Australian Heart Foundation guidelines).

💊

Perindopril

Coversyl® · Generic · ACE inhibitor

Adult dose 5 mg PO daily, titrate to 10 mg daily

Renal adjustment Start at 2.5 mg daily if eGFR <30 mL/min; monitor potassium

PBS status ✔ PBS General Benefit

💊

Amlodipine

Norvasc® · Generic · Calcium channel blocker

Adult dose 5 mg PO daily, titrate to 10 mg daily

Renal adjustment No adjustment required

PBS status ✔ PBS General Benefit

Beta-Blockers in Marfan Syndrome

Beta-blockers remain the first-line pharmacotherapy for Marfan syndrome to slow aortic root dilation. The proposed mechanism involves reducing aortic wall stress (dP/dt) through heart rate and blood pressure reduction.

ℹ️

Evidence summary: The Cochrane review (2017) and long-term observational data support beta-blocker use in Marfan syndrome, demonstrating a reduction in aortic root dilation rate of approximately 0.5–1.0 mm/year. Atenolol or metoprolol are preferred agents. If beta-blockers are contraindicated (asthma, severe bradycardia), losartan alone or verapamil may be considered.

💊

Metoprolol succinate

Betaloc CR® · Generic · β1-selective blocker (extended release)

Adult dose 50 mg PO daily, titrate to 100–200 mg daily (target HR <60 bpm)

Paediatric dose 1–2 mg/kg/day PO daily

Renal adjustment No adjustment required

PBS status ✔ PBS General Benefit

Smoking Cessation

Smoking is the single most important modifiable risk factor for AAA development, growth, and rupture. All patients with aortic aneurysm who smoke must be offered structured smoking cessation support.

💊

Varenicline

Champix® · Generic · Nicotinic receptor partial agonist

Adult dose 0.5 mg PO daily for Days 1–3, then 0.5 mg BD for Days 4–7, then 1 mg BD for 11 weeks (total 12 weeks; may repeat course)

Renal adjustment eGFR <30 mL/min: 0.5 mg daily throughout

PBS status ✔ PBS General Benefit (2 courses per 12 months)

💊

Nicotine replacement therapy (NRT)

Nicabate® · Generic · Nicotine patch + gum/lozenge combination

Adult dose Patch: 21 mg/24h (heavy smoker) or 14 mg/24h, taper over 8–12 weeks. Gum/lozenge: 2–4 mg PRN for breakthrough cravings.

PBS status ✔ PBS General Benefit (patches under co-payment; gum/lozenge OTC)

✅

Australian support services: Quitline (13 7848) provides free telephone counselling. The Quit programme (quit.org.au) offers online resources. GPs can claim MBS items for smoking cessation counselling (item 2517 — brief intervention; items 721/723 — GP Management Plan with smoking cessation goal). Referral to a smoking cessation specialist or respiratory physician may be appropriate for refractory dependence.

Statin Therapy

Statin therapy is recommended for all patients with aortic aneurysm, irrespective of baseline lipid levels. Statins reduce cardiovascular morbidity and mortality (which is the leading cause of death in AAA patients) and may have a modest anti-inflammatory effect on the aneurysm wall, although direct evidence for slowing AAA growth is inconclusive.

💊

Atorvastatin

Lipitor® · Generic · HMG-CoA reductase inhibitor

Adult dose 40–80 mg PO daily (high-intensity statin for secondary prevention)

Renal adjustment No adjustment required

Hepatic adjustment Contraindicated in active liver disease; caution in hepatic impairment

PBS status ✔ PBS General Benefit

💊

Rosuvastatin

Crestor® · Generic · HMG-CoA reductase inhibitor

Adult dose 20–40 mg PO daily

Renal adjustment Start at 5 mg daily if eGFR <30 mL/min (max 10 mg daily)

PBS status ✔ PBS General Benefit

Antiplatelet Therapy

Low-dose aspirin (100 mg daily) may be considered in patients with concomitant atherosclerotic cardiovascular disease. However, routine aspirin use in all AAA patients is not mandated due to the lack of evidence showing benefit on aneurysm progression and the potential for increased bleeding risk (particularly relevant in patients on anticoagulation for atrial fibrillation).

Summary — Medical Management Quick Reference

Blood pressure

ACEi/ARB ± CCB or beta-blocker

Target <130/80 mmHg

Lifelong

Marfan — aortic protection

Atenolol or metoprolol ± losartan

Target HR <60 bpm

Lifelong; specialist supervised

Smoking cessation

Varenicline + NRT + counselling

12-week course

Repeat if relapse

Lipid management

Atorvastatin 40–80 mg

Lifelong

Regardless of lipid levels

Special Populations

🤰

Pregnancy

Haemodynamic changes: Pregnancy increases cardiac output by 30–50% and blood volume by 40–50%, placing significant stress on the aortic wall. Risk of dissection is highest in the third trimester and peripartum period.

Marfan syndrome: Pre-conception aortic root assessment is mandatory. Prophylactic root replacement recommended if ≥4.5 cm before conception. If aortic root <4.0 cm, pregnancy may proceed with close echocardiographic surveillance (every trimester, then 6-weekly from 20 weeks).

Loeys-Dietz syndrome: Pregnancy is HIGH RISK. Multidisciplinary planning with obstetrics, cardiology, cardiothoracic surgery, and anaesthetics is essential.

Medications: Atenolol is teratogenic (FDA category D) — switch to metoprolol or labetalol. Losartan and all ARBs are contraindicated in pregnancy (teratogenic). ACE inhibitors are contraindicated. Statins should be ceased pre-conception.

Mode of delivery: Vaginal delivery with epidural and short second stage preferred if aortic root <4.0 cm. Caesarean section recommended if aortic root ≥4.0–4.5 cm or if there is significant aortic dilation.

Refer all women with aortic aneurysm or genetic aortopathy to a combined cardio-obstetric clinic (available at Royal Women's Hospital Melbourne, Mater Mothers' Brisbane, Royal Hospital for Women Sydney).

👶

Paediatrics

Paediatric aortic aneurysms are rare and almost always associated with genetic conditions (Marfan, LDS, Turner syndrome, bicuspid aortic valve, Williams syndrome).

Imaging: Echocardiography is the primary modality. MRI preferred over CT to reduce cumulative radiation in children. Use Z-scores (indexed to body surface area) for aortic root assessment — absolute diameter thresholds are unreliable in growing children.

Pharmacotherapy: Beta-blockers (atenolol 1–2 mg/kg/day or metoprolol 1–2 mg/kg/day) are first-line in Marfan syndrome. Losartan (0.7 mg/kg/day) may be added. Ensure regular growth monitoring.

Activity restriction: Avoid competitive sport and isometric exercise. Isotonic aerobic exercise at moderate intensity is permissible. Individualised exercise prescription guided by a sports cardiologist.

Surgical thresholds: Less defined in paediatrics; surgery considered when Z-score >5 or when rapid growth occurs despite optimal medical therapy.

Refer to a paediatric cardiology service (Royal Children's Hospital Melbourne, Children's Health Queensland, The Children's Hospital at Westmead).

👴

Elderly

Comorbidity burden: Elderly patients with AAA frequently have significant comorbidities (ischaemic heart disease, COPD, CKD, diabetes) that influence the decision to offer elective repair.

EVAR vs open: EVAR is preferred in elderly patients with significant comorbidities due to lower 30-day mortality and shorter recovery. However, lifelong surveillance requirements must be factored in.

Conservative management: May be appropriate for patients with limited life expectancy (<2 years), severe comorbidities precluding any intervention, or patient preference. This decision should be made in partnership with the patient and family.

Blood pressure targets: Cautious reduction in the very elderly (>80 years) to avoid orthostatic hypotension and falls — systolic target 130–150 mmHg may be acceptable.

Renal protection: Minimise contrast studies; use CO2 angiography or low-osmolar contrast with pre-hydration if imaging is required. Monitor renal function post-EVAR (contrast-induced nephropathy risk).

Functional status assessment (frailty scoring, e.g., Clinical Frailty Scale) should inform surgical decision-making. Consider referral for comprehensive geriatric assessment.

🫘

Renal Impairment

CKD prevalence: Approximately 20–30% of AAA patients have CKD (eGFR <60 mL/min). CKD is associated with faster aneurysm growth and higher operative mortality.

Contrast precautions: Use lowest possible contrast volume for CT angiography. Pre-hydrate with normal saline (1 mL/kg/h for 12 hours pre- and post-procedure). Consider CO2 angiography. Avoid metformin for 48 hours post-contrast if eGFR <30.

Drug adjustments: Reduce statin dose with caution (atorvastatin does not require renal dose adjustment; rosuvastatin max 10 mg if eGFR <30). Reduce amlodipine is not required. Adjust beta-blocker doses (atenolol dose reduction if eGFR <30). ARBs require potassium monitoring.

EVAR considerations: Suprarenal fixation stent-grafts may further compromise renal function. Monitor serum creatinine and eGFR at 1, 3, and 6 months post-EVAR.

Renal artery involvement in thoraco-abdominal aneurysms requires planning with renal perfusion preservation (fenestrated/branched endografts or renal artery reimplantation).

🛡️

Immunocompromised

Infective (mycotic) aneurysm: Immunocompromised patients (HIV, transplant recipients, chemotherapy) are at increased risk of mycotic aneurysm from bacteraemia (Salmonella, Staphylococcus aureus). These aneurysms are typically saccular, rapidly expanding, and require urgent surgical intervention combined with prolonged IV antibiotics (6 weeks minimum).

Inflammatory aortitis: Consider giant cell arteritis, IgG4-related disease, and other vasculitides as causes of aortic dilation in immunocompromised or immunosuppressed patients. Biopsy and immunosuppressive therapy (corticosteroids ± tocilizumab) may be required.

Post-operative infections: Prosthetic graft infections are a serious complication (mortality 25–50%). Higher risk in immunocompromised patients. Use prophylactic antibiotics per eTG guidelines; lifelong graft surveillance may be required.

Consult infectious disease specialist for any suspected mycotic aneurysm. Blood cultures (×3 sets) must be obtained before antibiotic initiation.

Aboriginal and Torres Strait Islander Health

Aboriginal and Torres Strait Islander Health Considerations

While the prevalence of AAA appears to be lower in Aboriginal and Torres Strait Islander populations compared to non-Indigenous Australians, the consequences of delayed diagnosis and limited access to vascular surgical services are disproportionately severe. Culturally safe healthcare delivery, community-based screening, and improved specialist access are critical to reducing the burden of aortic aneurysm disease.

Prevalence & Presentation

Australian Institute of Health and Welfare (AIHW) data suggest lower screening-detected AAA prevalence in Indigenous men, but this may reflect lower screening uptake rather than true lower prevalence. Indigenous Australians with AAA are more likely to present with rupture (emergency rather than elective diagnosis), contributing to higher case-fatality rates.

Cardiovascular Risk Factors

Aboriginal and Torres Strait Islander peoples experience significantly higher rates of smoking (40% vs 12% non-Indigenous), hypertension, diabetes, and chronic kidney disease — all established risk factors for aortic aneurysm. Rheumatic heart disease remains prevalent in remote communities and may contribute to aortic pathology.

Remote Access

Vascular surgical services are concentrated in major metropolitan centres. Patients in remote and very remote areas (particularly in the Northern Territory, Far North Queensland, and Western Australia) face significant barriers to accessing elective surgical repair, surveillance imaging, and specialist outpatient follow-up. Retrieval times for ruptured AAA can exceed 24 hours from some remote communities.

Screening Programmes

Current screening programmes are not systematically implemented in Aboriginal Community Controlled Health Services (ACCHS). Point-of-care ultrasound (POCUS) training for remote health practitioners and incorporation of AAA screening into Indigenous health checks (MBS item 715) is recommended. The Royal Flying Doctor Service (RFDS) may facilitate screening in remote communities.

Cultural Safety

Ensure culturally safe communication about aortic aneurysm, its asymptomatic nature, and the importance of screening. Use of Aboriginal health practitioners and interpreters where required. Respect for sorry business and cultural obligations when scheduling appointments and follow-up. Gender-concordant providers for examination when requested.

Smoking Cessation

Smoking rates in Indigenous populations remain approximately 3–4 times higher than in non-Indigenous Australians. Culturally specific smoking cessation programmes (Tackling Indigenous Smoking programme — now the National Tobacco Campaign) should be leveraged. Offer NRT and varenicline through ACCHS with follow-up from Aboriginal health workers.

Post-operative Follow-up

Post-EVAR surveillance requires regular CT or ultrasound imaging, which may be difficult in remote settings. Telehealth review with metropolitan vascular surgeons, facilitated by local health services, should be standard practice. RFDS and visiting specialist outreach programmes can provide intermittent ultrasound surveillance. Patient transport and accommodation support (through the Patient Assisted Travel Scheme — PATS) must be arranged for specialist appointments.

⚠️

Action items for primary care in Indigenous health settings:

Incorporate abdominal aortic ultrasound into MBS 715 health assessments for men aged ≥50 years (earlier threshold than non-Indigenous screening)
Aggressively manage cardiovascular risk factors — smoking cessation is the priority intervention
Establish pathways for vascular surgery referral through regional hospitals and ACCHS networks
Use telehealth to connect patients with metropolitan vascular specialists for ongoing surveillance
Advocate for expanded visiting vascular surgery and interventional radiology services to regional and remote centres

Investigations

Imaging is the cornerstone of aortic aneurysm diagnosis, surveillance, and operative planning. The choice of modality depends on the clinical context, anatomical location, patient factors, and need for procedural planning.

Essential Abdominal Ultrasound (AAA screening and surveillance) Sensitivity >95% for infrarenal AAA. Non-invasive, no radiation, widely available. MBS item 55208. First-line for screening and size-based surveillance.

Essential CT Aortography (CTA) Gold standard for operative planning. Provides detailed anatomical information (length, diameter, angulation, branch vessel involvement, calcification, thrombus). Essential for EVAR planning. MBS item 56300. Use low-osmolar contrast; pre-hydrate if eGFR <45.

Available MR Aortography (MRA) No radiation. Preferred in young patients and for serial surveillance to reduce cumulative radiation dose. Less accurate for calcification assessment. MBS item 63000 series. Contraindicated with non-MRI-safe implants.

Available Transthoracic Echocardiography (TTE) First-line for aortic root and ascending aorta assessment. Essential in Marfan syndrome and bicuspid aortic valve surveillance. Measures aortic root Z-scores (Devereux formula). MBS item 55118. Limited view of descending aorta.

Specialist Transoesophageal Echocardiography (TOE) Superior imaging of the descending thoracic aorta and aortic arch. Useful for intraoperative assessment and dissection evaluation. Requires sedation/GA. MBS item 55127.

Specialist Digital Subtraction Angiography (DSA) Largely replaced by CTA for diagnosis. Now reserved for intraoperative assessment during EVAR and adjunctive procedures (branch vessel stenting). MBS item 35600 series.

Referral Genetic Testing (Targeted Gene Panel) Indicated for suspected heritable aortopathy. Panels include FBN1, TGFBR1/2, SMAD3, COL3A1, ACTA2, MYH11. MBS items 73286–73304. Refer to clinical genetics service.

Baseline Investigations for All Patients with Aortic Aneurysm

Full blood count, renal function (eGFR), liver function tests, HbA1c, lipid profile
ECG — assess for ischaemic heart disease, LVH, arrhythmia
Echocardiography — assess aortic root, LV function, valvular disease
Ankle-brachial pressure index (ABPI) — assess for concomitant peripheral artery disease
Pulmonary function tests if COPD suspected — impacts fitness for open repair

📚 References

1. Wanhainen A, Verzini F, Van Herzeele I, et al. European Society for Vascular Surgery (ESVS) 2019 clinical practice guidelines on the management of abdominal aorto-iliac artery aneurysms. Eur J Vasc Endovasc Surg. 2019;57(1):8–93.
2. Erbel R, Aboyans V, Boileau C, et al. 2014 ESC guidelines on the diagnosis and treatment of aortic diseases. Eur Heart J. 2014;35(41):2873–2926.
3. Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease. Circulation. 2010;121(13):e266–e369.
4. Loeys BL, Dietz HC, Braverman AC, et al. The revised Ghent nosology for the Marfan syndrome. J Med Genet. 2010;47(7):476–485.
5. Loeys BL, Schwarze U, Holm T, et al. Aneurysm syndromes caused by mutations in the TGF-beta receptor. N Engl J Med. 2006;355(8):788–798.
6. Brady AR, Thompson SG, Fowkes FGR, Greenhalgh RM, Powell JT. Abdominal aortic aneurysm expansion: risk factors and time intervals for surveillance. Circulation. 2004;110(1):16–21.
7. United Kingdom Small Aneurysm Trial Participants. Long-term outcomes of immediate repair compared with surveillance of small abdominal aortic aneurysms. N Engl J Med. 2002;346(19):1445–1452.
8. IMPROVE Trial Investigators. Endovascular or open repair strategy for ruptured abdominal aortic aneurysm: 30 day outcomes from the IMPROVE randomised trial. BMJ. 2014;348:f7661.
9. Groenink M, den Hartog AW, Franken R, et al. Losartan reduces aortic rate of dilation in patients with Marfan syndrome: a randomised controlled trial (COMPARE). Eur Heart J. 2013;34(45):3491–3500.
10. Moll FL, Powell JT, Fraedrich G, et al. Management of abdominal aortic aneurysms: clinical practice guidelines of the European Society for Vascular Surgery. Eur J Vasc Endovasc Surg. 2011;41(Suppl 1):S1–S58.
11. Australian Institute of Health and Welfare (AIHW). Cardiovascular disease in Australia 2024. Canberra: AIHW; 2024.
12. Golledge J, Muller J, Daugherty A, Norman P. Abdominal aortic aneurysm: pathogenesis and implications for management. Arterioscler Thromb Vasc Biol. 2006;26(12):2605–2613.
13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023.
14. Bown MJ, Sutton AJ, Bell PR, Sayers RD. A meta-analysis of 50 years of ruptured abdominal aortic aneurysm repair. Br J Surg. 2002;89(6):714–730.
15. Devereux RB, de Simone G, Arnett DK, et al. Normal limits in relation to age, body size and gender of two-dimensional echocardiographic aortic root dimensions in persons ≥15 years of age. Am J Cardiol. 2012;110(8):1189–1194.